What is Crizotinib? How much?

Crizotinib (Crizotinib) is an oral targeted therapy drug mainly used to treat a specific type of cancer, namely tyrosine kinase fusion-positive non-small cell lung cancer (NSCLC).

NSCLC is one of the most common types of lung cancer, and it can be divided into different subtypes, one of which includes patients with ALK (Anaplastic Lymphoma Kinase) or ROS1 (c-ros Oncogene 1) Tumors with fusion genes. These fusion genes produce abnormal proteins, which in turn cause abnormal cell growth and proliferation, promoting tumor development. As a targeted therapy, crizotinib targets these abnormal ALK and ROS1 fusion proteins and inhibits their activity, thereby blocking abnormal cell proliferation and slowing down the development of cancer.

Crizotinib was originally developed by Pfizer (Pfizer), and was approved by the U.S. Food and Drug Administration (FDA) in 2011 under the trade name Xalkori®. The drug's approval confirms the important role of targeted therapy in the treatment of certain types of lung cancer, providing an effective treatment option for patients with ALK fusion-positive NSCLC or ROS1 fusion-positive NSCLC.

Crizotinib is currently on the market in China and is included in medical insurance. Patients can purchase it domestically, and the price is around 6,000~12,000 yuan. Since the price of medical insurance policies varies greatly across regions, please consult your local pharmacy or medical insurance bureau for specific prices. There are original and generic versions of crizotinib available abroad. The original version is mainly Pfizer’s original drug, and the price is around 11,000 yuan. Generic drugs are mainly from Bangladesh and Laos. Due to different pharmaceutical manufacturers and drug specifications, the price of generic drugs ranges from 2700~3000Yuan or so. Moreover, the ingredients of foreign original drugs and generic drugs are basically the same as those of domestic drugs.